Introduction

Gene editing and human enhancement law governs the modification of human genetic material to prevent disease, treat inherited conditions, improve biological functions or potentially alter physical and cognitive characteristics. Technologies such as CRISPR-Cas systems have created significant legal questions concerning bodily integrity, medical safety, reproductive autonomy, equality, privacy and the rights of future generations. The law distinguishes somatic gene editing, which affects non-reproductive cells, from germline editing, which may produce heritable genetic changes. Human enhancement raises additional concerns when genetic interventions are proposed for non-medical purposes rather than treating disease.

Legal and Regulatory Framework

There is no single comprehensive international treaty governing all forms of human gene editing. Regulation instead combines national legislation, medical research controls, human-rights principles and international bioethics standards.

The UNESCO Universal Declaration on the Human Genome and Human Rights (1997) emphasises human dignity, informed consent and protection against genetic discrimination. The World Health Organization's 2021 governance framework recommends robust oversight, transparency and international cooperation in human genome editing.

In China, the principal legal instruments include the Civil Code, Biosecurity Law, Criminal Law, Drug Administration Law and applicable rules on scientific and medical ethics. Article 1009 of the Civil Code requires human genetic and embryo research to comply with applicable laws and regulations, protect human health, respect ethical principles and avoid harm to public interests.

China's Criminal Law Article 336-1, introduced through the Eleventh Amendment effective in 2021, specifically criminalises certain unlawful implantations of gene-edited or cloned embryos. The provision distinguishes serious and especially serious circumstances and provides for imprisonment and fines.

Somatic Gene Editing and Medical Treatment

Somatic gene editing targets cells such as blood, liver or immune cells without intending to alter the genetic inheritance of future generations. Its legal pathway generally involves scientific validation, ethical review, informed consent, clinical-trial authorisation and applicable product approval.

Regulators must evaluate the reliability of clinical evidence, potential unintended genetic changes, immune responses, manufacturing quality and long-term safety. Patients must receive understandable information about uncertainties, alternatives and possible consequences. Approval for an experimental trial does not automatically authorise general commercial use.

Where gene editing is used for enhancement rather than treatment, additional questions arise concerning medical necessity, acceptable risk, fair access and the possibility of social pressure to undergo genetic interventions.

Germline Editing and Human Enhancement

Germline editing affects reproductive cells or embryos in ways that may be inherited by descendants. Its consequences can extend beyond the individual receiving an intervention, creating concerns about consent by future generations, irreversible effects and uncertainty about long-term outcomes.

The legal distinction between treatment and enhancement is important but not always straightforward. Preventing a severe inherited disease may have a different justification from attempting to select non-medical traits. Nevertheless, the claimed purpose of an intervention does not eliminate safety, ethical or legal requirements.

Human enhancement also raises equality concerns. If expensive genetic interventions become available only to wealthy groups, access disparities could increase. Genetic information may additionally create risks of discrimination in employment, insurance or social settings, depending on the applicable jurisdiction.

Case Laws and Judicial Developments

1. He Jiankui Case — Shenzhen, China (2019)

The Shenzhen Nanshan District People's Court convicted scientist He Jiankui and two collaborators for illegally conducting human embryo gene-editing experiments connected with reproductive treatment. He received three years' imprisonment and a fine of RMB 3 million; his collaborators also received criminal sentences. The court found that the researchers had acted without the required qualifications, violated relevant regulations and research ethics, and proceeded without adequately establishing safety and effectiveness. <Cite refs={["turn174858search0","turn174858search11"]}/>

This is a central legal development in human genome editing. However, the case concerned reproductive germline editing, not an otherwise authorised somatic gene therapy. Its broader significance lies in demonstrating that scientific novelty does not excuse violations of medical regulation, ethical review or patient protection.

2. Criminal Law Article 336-1 — China

This statutory provision, introduced after the He Jiankui incident, creates a specific offence involving unlawful implantation of gene-edited or cloned embryos. It strengthens criminal accountability for conduct that could result in heritable genetic modification. The provision is legislation, rather than a separate judicial precedent, and should be distinguished from the 2019 conviction, which relied on the criminal law applicable at that time. <Cite refs={["turn174858search2","turn174858search9"]}/>

3. Article 1009 of the Chinese Civil Code

Article 1009 provides a civil-law foundation for regulating human genetic and embryo research. Although it is not itself a reported court judgment, it supports the protection of human health, ethical standards and public interests. It may be relevant to disputes involving unlawful research, personality rights and potential civil liability.

4. International Governance Following the He Jiankui Incident

The WHO's 2021 governance framework is not a court judgment or binding international treaty. Nevertheless, it provides an important international benchmark for assessing oversight, accountability, research transparency and responsible clinical application. It reinforces the distinction between carefully regulated somatic therapies and heritable editing that raises additional ethical and intergenerational concerns.

Liability, Enforcement and Human Rights

Researchers, sponsors and medical institutions may face regulatory sanctions or civil or criminal liability where the applicable legal requirements are satisfied. Potential issues include inadequate informed consent, negligent research, unlawful clinical practice, improper disclosure of genetic information and failure to comply with approval conditions.

Legal safeguards should also protect privacy, prevent genetic discrimination and ensure that participants are not exposed to disproportionate risks. Human enhancement policies must consider equality, individual autonomy and the rights of people who may be affected by decisions made before they can consent.

Conclusion

Gene editing and human enhancement law seeks to balance scientific progress with human dignity, safety, equality and accountability. Somatic editing may offer important therapeutic opportunities under appropriate medical oversight, whereas heritable germline editing raises additional concerns for future generations. The He Jiankui case illustrates the consequences of unlawful reproductive gene-editing practices, while China's Civil Code and Criminal Law establish broader safeguards. Effective governance requires clear legislation, independent ethical review, informed consent, reliable scientific evidence and continuing public accountability.